Genzyme gets cold tissue welding technology:
This article was originally published in Clinica
Genzyme Tissue Repair will get exclusive rights for the development and commercialisation of PhotoBioMed's photoactive tissue welding technology for all orthopaedic purposes. Genzyme will make an initial payment to the Dallas-based company and subsequent milestone and royalty payments. PhotoBioMed's technology uses a photochemical compound which, when light activated, interacts with collagen fibres in the tissue, cross-linking the proteins and welding torn tissue without heat. Genzyme, of Cambridge, Massachusetts, will first develop applications for meniscal repair.
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.